University of California San Francisco
San Francisco, California, 94610, United States
NCT Number: NCT01150591
Hypothesis 1: Microaspiration, as diagnosed by bronchoalveolar lavage (BAL) pepsin, is common in patients with IPF.
Hypothesis 2a: Baseline clinical variables and co-morbid conditions are risk factors for microaspiration in patients with IPF.
Hypothesis 2b: Baseline biological variables reflecting alveolar epithelial injury and inflammation are markers of microaspiration in IPF.
Hypothesis 3a: Microaspiration will lead to a more rapid rate of decline in pulmonary function.
Hypothesis 3b: Microaspiration will lead to higher rates of urgent medical care use (i.e. unscheduled clinic visit, emergency room visit, or hospitalization).
Looking for future studies?
Notify Me18 year–100 year
All sexes
Observational
San Francisco, California, 94610, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Cross sectional
Looking for future studies?
Notify MeUniversity of California, San Francisco
Other
The Role of Microaspiration in Idiopathic Pulmonary Fibrosis
Acronym: ROMI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04071769
Idiopathic Pulmonary Fibrosis, Lung Diseases
Durham, North Carolina, United States
View Trial DetailsNCT06241560
Idiopathic Pulmonary Fibrosis, Lung Diseases
The Woodlands, Texas, United States
View Trial DetailsNCT05671835
Idiopathic Pulmonary Fibrosis, Lung Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05537025
Idiopathic Pulmonary Fibrosis, Lung Diseases
Copenhagen, Denmark
View Trial Details